Abstract
Percutaneous image-guided ablation is an accepted treatment for nonsurgical candidates with limited tumor burden and appropriate location. This report investigates a single center 4-year survival in patients with biopsy proven malignant renal neoplasms.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
